文献速递肝病

Seladelpar改善原发性胆汁性胆管炎瘙痒患者瘙痒、睡眠障碍及疲劳

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2026-04-03

RESPONSE 3期试验中,对熊去氧胆酸应答不足或不耐受的PBC患者按2:1随机接受seladelpar 10 mg或安慰剂治疗12个月。在基线NRS≥4的患者中,seladelpar使瘙痒从中度改善至轻度,并减少瘙痒身体分布、改善瘙痒相关睡眠障碍,在基线重度瘙痒患者中疲劳指标优于安慰剂。

要点

  • Seladelpar 10 mg治疗12个月可改善PBC患者中度至重度瘙痒。
  • Seladelpar减少瘙痒身体分布并改善瘙痒相关睡眠障碍。
  • 基线重度瘙痒患者中,seladelpar的疲劳指标优于安慰剂。

核心结论

  • 除已确立的抗胆汁淤积作用外,seladelpar改善PBC瘙痒患者的瘙痒严重程度与分布、瘙痒相关睡眠障碍及疲劳指标。

研究设计与样本

  • RESPONSE为3期试验(NCT04620733),对熊去氧胆酸应答不足或不耐受的PBC患者按2:1随机接受seladelpar 10 mg或安慰剂治疗12个月。

主要发现

  • 基线NRS≥4的患者中,seladelpar组平均NRS从中度改善至轻度,安慰剂组未出现该改善。
  • 基于5-D瘙痒分布域,seladelpar减少瘙痒的身体分布范围。
  • seladelpar在各人群中一致改善瘙痒相关睡眠障碍。
  • 基线重度瘙痒患者中,seladelpar的疲劳指标优于安慰剂。
  • 无瘙痒患者倾向维持无瘙痒,且seladelpar的瘙痒不良事件少于安慰剂。

关键数值与推荐

  • 瘙痒严重程度采用数值评定量表(NRS)评估,分析人群包括基线NRS≥4、NRS≥7及PBC-40瘙痒≥7者。
  • 瘙痒相关指标采用5-D瘙痒量表和PBC-40评估。

临床怎么用

  • 对于PBC伴瘙痒患者,seladelpar除改善胆汁淤积指标外,还可能改善瘙痒严重程度、分布、睡眠障碍及疲劳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pruritus and fatigue impose a significant burden on patient quality of life in primary biliary cholangitis (PBC). In the Phase 3 RESPONSE trial (NCT04620733), seladelpar, a potent and selective PPARδ agonist, significantly improved markers of cholestasis and pruritus. AIMS: Here, we provide additional details on the effects of seladelpar on pruritus and quality of life. METHODS: In RESPONSE, patients with PBC and an inadequate response or intolerance to ursodeoxycholic acid were randomised 2:1 to seladelpar 10 mg or placebo for 12 months. Changes in severity of pruritus by the numeric rating scale (NRS) and changes in 5-D Itch and PBC-40 in patients with moderate to severe itch (NRS ≥ 4), severe itch (NRS ≥ 7) and clinically significant itch (PBC-40 itch ≥ 7) at baseline were evaluated. RESULTS: In patients with baseline NRS ≥ 4, mean NRS improved from the moderate to mild range with seladelpar, but not placebo. Bodily distribution of itch was reduced with seladelpar based on the 5-D itch distribution domain. Itch-related sleep disturbance was consistently improved with seladelpar across populations, and measures of fatigue were improved versus placebo in patients with severe itch at baseline. Patients without itching tended to remain free from itching with seladelpar, consistent with fewer adverse events of pruritus with seladelpar versus placebo. CONCLUSION: In addition to an established anticholestatic effect, seladelpar improved pruritus severity and distribution, itch-related sleep disturbance and measures of fatigue in patients with PBC and pruritus, indicating clinically relevant improvements in itch and other quality of life benefits.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Levy C, Jones DEJ, Mayo MJ, et al. Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. Aliment Pharmacol Ther. 2026. PMID: 41933275. doi:10.1111/apt.70630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。